Series A financing co-led by Westlake Village BioPartners and Versant Ventures Company advancing systemically delivered, skeletal and cardiac muscle targeted, liver de-targeted capsid and cargo technology platforms Initial pipeline addressing myotonic dystrophy type 1 and…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.